2seventy bio Inc Ordinary Shares TSVT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TSVT is a good fit for your portfolio.
News
-
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma
-
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
-
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
-
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
-
Thinking about buying stock in Solidion Technology, Nuvei, 2Seventy Bio, Aeye, or DHC Acquisition?
-
Thinking about buying stock in 2Seventy Bio, Verb Technology, Exscientia, MicroCloud Hologram, or Akebia Therapeutics?
-
2seventy Bio Shares Soar Premarket as FDA Panel Backs Abecma
-
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Trading Information
- Previous Close Price
- $4.52
- Day Range
- $4.35–4.72
- 52-Week Range
- $1.54–12.69
- Bid/Ask
- $4.64 / $4.75
- Market Cap
- $238.60 Mil
- Volume/Avg
- 406,373 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 425
- Website
- https://www.2seventybio.com
Comparables
Valuation
|
Metric
|
TSVT
|
SLRN
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.96 | 0.73 | 0.82 |
Price/Sales | 2.39 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TSVT
|
SLRN
|
VOR
|
|---|---|---|---|
Quick Ratio | 3.85 | 8.53 | 8.81 |
Current Ratio | 3.98 | 8.65 | 9.04 |
Interest Coverage | — | — | — |
Quick Ratio
TSVT
SLRN
VOR
Profitability
|
Metric
|
TSVT
|
SLRN
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −24.84% | −57.50% | −41.83% |
Return on Equity (Normalized) | −50.12% | −88.66% | −51.69% |
Return on Invested Capital (Normalized) | −29.90% | −96.26% | −47.03% |
Return on Assets
TSVT
SLRN
VOR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jzycwgghl | Bxh | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Npwxrtrdv | Xnrqj | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mkwxdhwf | Qnthgs | $98.8 Bil | |
MRNA
| Moderna Inc | Lfcyjjwr | Ngjr | $38.8 Bil | |
ARGX
| argenx SE ADR | Cftknvgt | Vcdxn | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Qlvvjfqgv | Qnsqh | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mpfbsjt | Mhcnl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dfhmtmbnd | Ffczp | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pcfslflxf | Ljzytn | $12.4 Bil | |
INCY
| Incyte Corp | Sqhgpnkl | Chnnhvx | $11.9 Bil |